Insights

Ian Riddock, MD, and Eliot Brinton, MD, discuss effective use of lipid lowering therapies in patients with atherosclerotic cardiovascular disease (ASCVD).

Shared insight on the role cardiovascular disease management plays in the prostate cancer treatment paradigm.

Ryan Haumschild, PharmD, MS, MBA, and Kathy Oubre, MS, discuss the use of biosimilars at their organizations and what payers should be thinking about when considering biosimilar transitions.

X. Long Zheng, MD, PhD, gives an overview of acquired thrombotic thrombocytopenic purpura and the treatment considerations for the disease.

Rheumatologist Ellen Ginzler, MD, MPH, and nephrologist German Hernandez, MD, FASN, FACP, explore the current treatment landscape of lupus nephritis and the managed care considerations of recent FDA approved therapies for the disease.

Key opinion leaders discuss the key differences and unmet needs in disease management for heart failure with preserved ejection fraction and heart failure with reduction ejection fraction.

Oncologists explore the opportunity of CAR T-cell therapy for the treatment of relapsed/refractory multiple myeloma.

A clinician and payer discuss the impact of chemotherapy-induced neutropenia on patients as well as the healthcare system, and discuss the latest in prophylactic treatment, especially during the COVID-19 pandemic.

Examining current treatment options for brain metastases in metastatic HER2+ breast cancer and assessing the clinical and economic burden.

The impact of the COVID-19 pandemic on managing HIV and strategies implemented to address challenges faced by providers.